A detailed history of Nuveen Asset Management, LLC transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 60,438 shares of FHTX stock, worth $473,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,438
Previous 67,866 10.95%
Holding current value
$473,833
Previous $390,000 44.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.8 - $9.99 $35,654 - $74,205
-7,428 Reduced 10.95%
60,438 $562,000
Q2 2024

Aug 09, 2024

BUY
$5.05 - $8.0 $70,210 - $111,224
13,903 Added 25.76%
67,866 $390,000
Q4 2023

Feb 14, 2024

BUY
$2.94 - $6.76 $1,420 - $3,265
483 Added 0.9%
53,963 $348,000
Q1 2023

May 15, 2023

SELL
$4.66 - $8.99 $2,250 - $4,342
-483 Reduced 0.9%
53,480 $331,000
Q4 2022

Feb 14, 2023

SELL
$5.44 - $9.46 $16,809 - $29,231
-3,090 Reduced 5.42%
53,963 $345,000
Q3 2022

Nov 14, 2022

SELL
$7.52 - $18.01 $19,183 - $45,943
-2,551 Reduced 4.28%
57,053 $490,000
Q2 2022

Aug 15, 2022

SELL
$8.48 - $16.84 $451,729 - $897,066
-53,270 Reduced 47.19%
59,604 $811,000
Q1 2022

May 16, 2022

BUY
$8.87 - $22.1 $584,417 - $1.46 Million
65,887 Added 140.22%
112,874 $1.52 Million
Q4 2021

Feb 14, 2022

SELL
$10.79 - $22.87 $71,073 - $150,644
-6,587 Reduced 12.3%
46,987 $837,000
Q3 2021

Nov 12, 2021

SELL
$8.33 - $15.02 $23,623 - $42,596
-2,836 Reduced 5.03%
53,574 $709,000
Q2 2021

Aug 16, 2021

BUY
$9.32 - $13.26 $415,699 - $591,435
44,603 Added 377.77%
56,410 $602,000
Q4 2020

Feb 16, 2021

BUY
$15.12 - $25.88 $178,521 - $305,565
11,807 New
11,807 $239,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $326M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.